Tuned activation of MSLN-CAR T cells induces superior antitumor responses in ovarian cancer models

Decade-long leukaemia remissions with persistence of CD4+ CAR T cells

(2022) J. Joseph Melenhorst et al.   NATURE

Trogocytosis and fratricide killing impede MSLN-directed CAR T cell functionality

(2022) Esther Schoutrop et al.   OncoImmunology

Balancing activation and co-stimulation of CAR tunes signaling dynamics and enhances therapeutic potency

(2022) Yanting Duan et al.   MOLECULAR THERAPY

Mesothelin-specific CAR T cells target ovarian cancer

(2021) Esther Schoutrop et al.   CANCER RESEARCH

Combination therapy with CAR T cells and oncolytic viruses: a new era in cancer immunotherapy

(2021) Ramazan Rezaei et al.   CANCER GENE THERAPY

A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab

(2021) Prasad S Adusumilli et al.   Cancer Discovery

T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours

(2021) Stefanie Lesch et al.   Nature Biomedical Engineering

A BCL2L1 Armoured BCMA Targeting CAR T Cell to Overcome Exhaustion and Enhance Persistence in Multiple Myeloma

(2021) Ranjan Maity et al.   BLOOD

An NK-like CAR T cell transition in CAR T cell dysfunction

(2021) Charly R. Good et al.   CELL

136 ATA3271: An armored, next-generation off-the-shelf, allogeneic, mesothelin-CAR T cell therapy for solid tumors

(2021) Xianhui Chen et al.   Journal for ImmunoTherapy of Cancer

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma

(2020) Michael Wang et al.   NEW ENGLAND JOURNAL OF MEDICINE

IL-15 Preconditioning Augments CAR T Cell Responses to Checkpoint Blockade for Improved Treatment of Solid Tumors

(2020) Lauren Giuffrida et al.   MOLECULAR THERAPY

Noncanonical binding of Lck to CD3ε promotes TCR signaling and CAR function

(2020) Frederike A. Hartl et al.   NATURE IMMUNOLOGY

Coexpression of IL7 and CCL21 Increases Efficacy of CAR-T Cells in Solid Tumors without Requiring Preconditioned Lymphodepletion

(2020) Hong Luo et al.   CLINICAL CANCER RESEARCH

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

(2020) Jeremy S Abramson et al.   LANCET

CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape

(2019) Mohamad Hamieh et al.   NATURE

Phase I study of lentiviral-transduced chimeric antigen receptor modified T cells recognizing mesothelin in advanced solid cancers

(2019) Andrew R. Haas et al.   MOLECULAR THERAPY

Modified CAR T cells targeting membrane-proximal epitope of mesothelin enhances the antitumor function against large solid tumor

(2019) Zhiwei Zhang et al.   Cell Death & Disease

Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors

(2019) Rachel Grosser et al.   CANCER CELL

Single-cell transcriptomics of human T cells reveals tissue and activation signatures in health and disease

(2019) Peter A. Szabo et al.   Nature Communications

Engineered triple inhibitory receptor resistance improves anti-tumor CAR-T cell performance via CD56

(2019) Fan Zou et al.   Nature Communications

Media evaluation for production and expansion of anti-CD19 chimeric antigen receptor T cells

(2018) Rehab Alnabhan et al.   CYTOTHERAPY

CD19 Chimeric Antigen Receptor T Cells From Patients With Chronic Lymphocytic Leukemia Display an Elevated IFN-γ Production Profile

(2018) Isabelle Magalhaes et al.   JOURNAL OF IMMUNOTHERAPY

Understanding the tumor immune microenvironment (TIME) for effective therapy

(2018) Mikhail Binnewies et al.   NATURE MEDICINE

Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency

(2018) Judith Feucht et al.   NATURE MEDICINE

Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection

(2017) Justin Eyquem et al.   NATURE

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

(2017) Sattva S. Neelapu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition

(2016) Leonid Cherkassky et al.   JOURNAL OF CLINICAL INVESTIGATION

Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors

(2015) A. Morello et al.   Cancer Discovery

Functional Tuning of CARs Reveals Signaling Threshold above Which CD8+ CTL Antitumor Potency Is Attenuated due to Cell Fas-FasL-Dependent AICD

(2015) A. Kunkele et al.   Cancer Immunology Research

Preferential Recruitment of Th17 Cells to Cervical Cancer via CCR6-CCL20 Pathway

(2015) Qing Yu et al.   PLoS One

Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity

(2014) P. S. Adusumilli et al.   Science Translational Medicine

Influence of tumour micro-environment heterogeneity on therapeutic response

(2013) Melissa R. Junttila et al.   NATURE

Identification ofAcvr2aas a Th17 Cell-Specific Gene Induced during Th17 Differentiation

(2011) Hyun-ju IHN et al.   BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY

Th17 Cells Are Long Lived and Retain a Stem Cell-like Molecular Signature

(2011) Pawel Muranski et al.   IMMUNITY

T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

(2011) M. Kalos et al.   Science Translational Medicine

Construction and Preclinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor

(2009) James N. Kochenderfer et al.   JOURNAL OF IMMUNOTHERAPY

Tumor-specific Th17-polarized cells eradicate large established melanoma

(2008) P. Muranski et al.   BLOOD

T Helper 17 Lineage Differentiation Is Programmed by Orphan Nuclear Receptors RORα and RORγ

(2008) Xuexian O. Yang et al.   IMMUNITY

Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates

(2008) Carolina Berger et al.   JOURNAL OF CLINICAL INVESTIGATION